Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

Morgan Stanley analyst Vikram Purohit lowered the firm’s price target on Legend Biotech (LEGN) to $80 from $82 and keeps an Overweight rating ...

5 analysts have shared their evaluations of Legend Biotech (NASDAQ:LEGN) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their ...

In a report released today, Gena Wang from Barclays maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a price target of ...